Transfusion Medicine Reviews
Volume 21 , Pages S9-S56 , April 2007

Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions

References 

  1. Feasby TE: Appropriateness of IVIG—hematology summaries (unpublished).
  2. Biotext Science Information Consultants . A systematic literature review and report on the efficacy of intravenous immunoglobulin therapy and its risks. Final Report v04. Australian National Blood Authority; 2004;www.nba.gov.au/pubs.htm
  3. Chalmers Research Institute: IVIG systematic reviews. (unpublished)
  4. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17:241–251
  5. Phillips B, Ball C, Sackett D, et al. Levels of evidence. www.eboncall.org/content/levels.html2002;
  6. Browman GP, Newman TE, Mohide EA, et al. Progress of clinical oncology guidelines development using the practice guidelines development cycle: The role of practitioner feedback. J Clin Oncol. 1998;16:1226–1231
  7. Crenier L, Ducobu J, des Grottes JM, et al. Low response to high-dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor. Br J Haematol. 1996;95:750–753
  8. Dykes AC, Walker ID, Lowe GD, et al. Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: A 2-year review. Haemophilia. 2001;7:160–163
  9. Boughton BJ, Jackson N, Lim S, et al. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol. 1995;17:75–80
  10. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319:902–907
  11. Chapel H, Dicato M, Gamm H, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: A comparison of 2 dose regimes. Br J Haematol. 1994;88:209–212
  12. Gamm H, Huber C, Chapel H, et al. Intravenous immune globulin in chronic lymphocytic leukaemia. Clin Exp Immunol. 1994;97:17–20(Suppl 1)
  13. Griffiths H, Brennan V, Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood. 1989;73:366–368
  14. Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica. 1996;81:121–126
  15. Chapel HM, Lee M, Hargreaves R, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet. 1994;343:1059–1063
  16. Hargreaves RM, Lea JR, Holt J, et al. Infection, immune responses and IV immunoglobulin infection prophylaxis in myeloma. (abstract) Br J Cancer. 1992;66:261;(Suppl XVII)
  17. Schedel I. Intravenous immunoglobulin replacement in secondary antibody deficiency syndrome. Diagn Intensivther. 1982;7:254–263
  18. Gebauer E, Tomic J, Stevanovic S. Intravenous immunoglobulin in the treatment of infections in children with acute leukemias. Med Pregl. 1994;47:52–55
  19. Gimesi A, Eibl M, Koos R, et al. Immunoglobulin prophylaxis during intensive treatment of acute lymphoblastic leukemia in children. Acta Paediatr Hung. 1992;32:115–125
  20. Sumer T, Abumelha A, al-Mulhim I, et al. Treatment of fever and neutropenia with antibiotics versus antibiotics plus intravenous gammaglobulin in childhood leukemia. Eur J Pediatr. 1989;148:401–402
  21. Hayakawa F, Imada K, Towatari M, et al. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol. 2002;118:1187–1189
  22. Ballester OF, Saba HI, Moscinski LC, et al. Pure red cell aplasia: Treatment with intravenous immunoglobulin concentrate. Semin Hematol. 1992;29:106–108(3 Suppl 2)
  23. Casadevall N, Lacombe C, Varet B. Erythroblastopenia: Chronic idiopathic or associated with chronic lymphoid leukemia. Value of cultures of erythroblastic progenitors and therapeutic strategy. Presse Med. 1993;22:1079–1086
  24. Castelli R, Vismara A, Pavia G, et al. Relapsing pure red cell aplasia associated with B-cell chronic lymphocytic leukemia successfully treated by intravenous immunoglobulin concentrate. Ann Ital Med Int. 2002;17:47–50
  25. Clauvel JP, Vainchenker W, Herrera A, et al. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins. Br J Haematol. 1983;55:380–382
  26. Cobcroft R. Pure red cell aplasia associated with small lymphocytic lymphoma. Br J Haematol. 2001;113:260
  27. Ilan Y, Naparstek Y. Pure red cell aplasia associated with systemic lupus erythematosus: Remission after a single course of intravenous immunoglobulin. Acta Haematol. 1993;89:152–154
  28. Huang JL, Hung IJ, Chen LC, et al. Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin. Clin Rheumatol. 1998;17:349–352
  29. Larroche C, Mouthon L, Casadevall N, et al. Successful treatment of thymoma-associated pure red cell aplasia with intravenous immunoglobulins. Eur J Haematol. 2000;65:74–76
  30. Mant MJ. Chronic idiopathic pure red cell aplasia: Successful treatment during pregnancy and durable response to intravenous immunoglobulin. J Intern Med. 1994;236:593–595
  31. McGuire WA, Yang HH, Bruno E, et al. Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med. 1987;317:1004–1008
  32. Needleman SW. Durable remission of pure red cell aplasia after treatment with high-dose intravenous gammaglobulin and prednisone. Am J Hematol. 1989;32:150–152
  33. Ohashi K, Akiyama H, Takamoto S, et al. Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplantation Team. Bone Marrow Transplant. 1994;13:335–336
  34. Roychowdhury DF, Linker CA. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant. 1995;16:471–472
  35. Amiot L, Langanay T, Drenou B, et al. Spontaneous recovery from severe parvovirus B19 pure red cell aplasia, in a heart transplant recipient, as demonstrated by marrow culture. Hematol Cell Ther. 1998;40:71–73
  36. Koduri PR, Kumapley R, Khokha ND, et al. Red cell aplasia caused by parvovirus B19 in AIDS: Use of I.V. immunoglobulin. Ann Hematol. 1997;75:67–68
  37. Koduri PR, Kumapley R, Valladares J, et al. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: Use of intravenous immunoglobulin—a report of 8 patients. Am J Hematol. 1999;61:16–20
  38. Kondo H, Mori A, Watanabe J, et al. Pure red cell aplasia associated with parvovirus B19 infection in T-large granular lymphocyte leukemia. Leuk Lymphoma. 2001;42:1439–1443
  39. Wong TY, Chan PK, Leung CB, et al. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am J Kidney Dis. 1999;34:1132–1136
  40. Federici AB, Stabile F, Castaman G, et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of 3 different therapeutic approaches. Blood. 1998;92:2707–2711
  41. Bergen GA, Sakalosky PE, Sinnott JT. Transient aplastic anemia caused by parvovirus B19 infection in a heart transplant recipient. J Heart Lung Transplant. 1996;15:843–845
  42. Bourantas K, Makrydimas G, Georgiou I, et al. Aplastic anemia. Report of a case with recurrent episodes in consecutive pregnancies. J Reprod Med. 1997;42:672–674
  43. Chen SH, Liang DC, Lin M. Treatment of platelet alloimmunization with intravenous immunoglobulin in a child with aplastic anemia. Am J Hematol. 1995;49:165–166
  44. Chen RL, Lin KH, Lin DT, et al. Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol. 1995;89:282–290
  45. Kapoor N, Hvizdala E, Good RA. High dose intravenous gammaglobulin as an approach to treatment of antibody mediated pancytopenia. Br J Haematol. 1988;69:98–99
  46. De Lord C, Marsh JC, Smith JG, et al. Fatal autoimmune pancytopenia following bone marrow transplantation for aplastic anaemia. Bone Marrow Transplant. 1996;18:237–239
  47. Lutz P, Gallais C, Albert A, et al. Use of intravenous immunoglobulins (IVIg) to treat a child with pancytopenia and hypoplastic marrow. Ann Hematol. 1992;65:199–200
  48. Salim S, Salim KA. Chicken pox induced pancytopenia and prompt response to high dose intravenous immunoglobulin. J Assoc Physicians India. 1992;40:689–690
  49. Sherer Y, Levy Y, Fabbrizzi F, et al. Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIg)—report of 7 cases and review of the literature. Eur J Intern Med. 2000;11:85–88
  50. Flores G, Cunningham-Rundles C, Newland AC, et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: Results in 73 patients. Am J Hematol. 1993;44:237–242
  51. Bussel J, Lalezari P, Hilgartner M, et al. Reversal of neutropenia with intravenous gammaglobulin in autoimmune neutropenia of infancy. Blood. 1983;62:398–400
  52. Bussel J, Lalezari P, Fikrig S. Intravenous treatment with gamma-globulin of autoimmune neutropenia of infancy. J Pediatr. 1988;112:298–301
  53. Bux J, Behrens G, Jaeger G, et al. Diagnosis and clinical course of autoimmune neutropenia in infancy: Analysis of 240 cases. Blood. 1998;91:181–186
  54. Gordon BG, Kiwanuka J, Kadushin J. Autoimmune neutropenia and Hodgkin's disease: Successful treatment with intravenous gammaglobulin. Am J Pediatr Hematol Oncol. 1991;13:164–167
  55. Hilgartner MW, Bussel J. Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am J Med. 1987;83:25–29
  56. Mascarin M, Ventura A. Anti-Rh(D) immunoglobulin for autoimmune neutropenia of infancy. Acta Paediatr. 1993;82:142–144
  57. Sorensen RU, Kallick MD. Clinical uses of intravenous immune globulin: Immunoglobulin replacement therapy and treatment of autoimmune cytopenias. J Clin Apheresis. 1988;4:97–103
  58. Alliot C, Barrios M, Tabuteau S, et al. Autoimmune cytopenias associated with malignancies and successfully treated with intravenous immune globulins: About two cases. Therapie. 2000;55:371–374
  59. Schoengen A, Fembacher PM, Schulz PC. Immunoglobulin therapy for autoimmune neutropenia in Hodgkin's disease. Acta Haematol. 1995;94:36–38
  60. Young NS, Abkowitz JL, Luzzatto L. New insights into the pathophysiology of acquired cytopenias. Hematology (Am Soc Hematol Educ Program). 2000;18–38
  61. Scaradavou A, Bussel J. Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol. J Pediatr Hematol Oncol. 1995;17:290–295
  62. Mathew P, Chen G, Wang W. Evans syndrome: Results of a national survey. J Pediatr Hematol Oncol. 1997;19:433–437
  63. Ucar B, Akgun N, Aydogdu SD, et al. Treatment of refractory Evans' syndrome with cyclosporine and prednisone. Pediatr Int. 1999;41:104–107
  64. Gombakis N, Trahana M, Athanassiou M, et al. Evans syndrome: Successful management with multi-agent treatment including intermediate-dose intravenous cyclophosphamide. J Pediatr Hematol Oncol. 1999;21:248–249
  65. Chang DK, Yoo DH, Kim TH, et al. Induction of remission with intravenous immunoglobulin and cyclophosphamide in steroid-resistant Evans' syndrome associated with dermatomyositis. Clin Rheumatol. 2001;20:63–66
  66. Muwakkit S, Rachid R, Bazarbachi A, et al. Treatment-resistant infantile Evans syndrome. Pediatr Int. 2001;43:502–504
  67. Muwakkit S, Locatelli F, Abboud M, et al. Report of a child with vitiligo and Evans syndrome. J Pediatr Hematol Oncol. 2003;25:344–345
  68. Petrides PE, Hiller E. Autoimmune hemolytic anemia combined with idiopathic thrombocytopenia (Evans syndrome). Sustained remission in a patient following high-dose intravenous gamma-globulin therapy. Clin Investig. 1992;70:38–39
  69. Friedmann AM, King KE, Shirey RS, et al. Fatal autoimmune hemolytic anemia in a child due to warm-reactive immunoglobulin M antibody. J Pediatr Hematol Oncol. 1998;20:502–505
  70. Qureshi S, Zaman S, Iqbal J. Intravenous immunoglobulin G therapy in Evans syndrome. J Pak Med Assoc. 2000;50:321–323
  71. Bolis S, Marozzi A, Rossini F, et al. High dose intravenous immunoglobulin (IVIgG) in Evans' syndrome. Allergol Immunopathol (Madr). 1991;19:186
  72. Kaplan C, Murphy MF, Kroll H, et al. Feto-maternal alloimmune thrombocytopenia: Antenatal therapy with IvIgG and steroids—more questions than answers. Br J Haematol. 1998;100:62–65
  73. Gaddipati S, Berkowitz RL, Lembet AA, et al. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 incompatibility. Am J Obstet Gynecol. 2001;185:976–980
  74. Giers G, Hoch J, Bauer H, et al. Therapy with intravenous immunoglobulin G (ivIgG) during pregnancy for fetal alloimmune (HPA-1a(Zwa)) thrombocytopenic purpura. Prenat Diagn. 1996;16:495–502
  75. Silver RM, Porter TF, Branch DW, et al. Neonatal alloimmune thrombocytopenia: Antenatal management. Am J Obstet Gynecol. 2000;182:1233–1238
  76. Kornfeld I, Wilson RD, Ballem P, et al. Antenatal invasive and noninvasive management of alloimmune thrombocytopenia. Fetal Diagn Ther. 1996;11:210–217
  77. Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: A randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol. 1996;174:1414–1423
  78. Birchall JE, Murphy MF, Kaplan C, et al. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol. 2003;122:275–288
  79. Cordonnier C, Chevret S, Legrand M, et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med. 2003;139:8–18
  80. Abdel-Mageed A, Graham-Pole J, Del Rosario ML, et al. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone Marrow Transplant. 1999;23:929–932
  81. Feinstein LC, Seidel K, Jocum J, et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant. 1999;5:369–378
  82. Winston DJ, Antin JH, Wolff SN, et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001;28:187–196
  83. Winston DJ, Ho WG, Bartoni K, et al. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant. 1993;12:283–288
  84. Winston DJ, Ho WG, Lin CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987;106:12–18
  85. Zikos P, Van Lint MT, Lamparelli T, et al. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica. 1998;83:132–137
  86. Ruutu T, Ljungman P, Brinch L, et al. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group. Bone Marrow Transplant. 1997;19:233–236
  87. Bowden RA, Fisher LD, Rogers K, et al. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis. 1991;164:483–487
  88. Lum L, Bitonti O, Jin NR, et al. Intravenous gamma-globulin (IVIG) does not alter immune parameters in a randomized trial after bone-marrow transplantation (BMT). Exp Hematol. 1994;22:680
  89. Pole JG. Preventing systemic infections with IVIG: A randomized multicenter trial. Bone Marrow Transplant. 1990;5:132;(suppl 2)
  90. Poynton CH, Jackson S, Fegan C, et al. Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplantation. 1992;9:451–457
  91. Sullivan KM, Storek J, Kopecky KJ, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant. 1996;2:44–53
  92. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705–712
  93. Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med. 1993;118:937–942
  94. Aldan H, Cordonnier C. Antimicrobial prophylaxis in EBMT centers : A report from the Infectious Diseases Working Party.. Bone Marrow Transplant. 2001;27:S202;Suppl 1, abstr
  95. American Academy of Pediatrics . Subcommittee on hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114:297–316
  96. Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003;88:F6–F10
  97. Alcock GS, Liley H. Systematic review: Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev. 2002;CD003313
  98. Alpay F, Sarici SU, Okutan V, et al. High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr. 1999;88:216–219
  99. Dagoglu T, Ovali F, Samanci N, et al. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J Int Med Res. 1995;23:264–271
  100. Rubo J, Albrecht K, Lasch P, et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr. 1992;121:93–97
  101. Woodcock BE, Walker S, Adams K. Haemolytic transfusion reaction—Successful attenuation with methylprednisolone and high dose immunoglobulin. Clin Lab Haematol. 1993;15:59–61
  102. Kohan AI, Niborski RC, Rey JA, et al. High-dose intravenous immunoglobulin in non-ABO transfusion incompatibility. Vox Sang. 1994;67:195–198
  103. Cullis JO, Win N, Dudley JM, et al. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: Use of steroids and intravenous immunoglobulin to prevent further red cell destruction. Vox Sang. 1995;69:355–357
  104. Gangarossa S, Lucini NR. High-dose intravenous immunoglobulin therapy, blood rheology, and sickle cell anemia. Pediatr Hematol Oncol. 1993;10:377–378
  105. Win N, Doughty H, Telfer P, et al. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion. 2001;41:323–328
  106. Robson WL, Fick GH, Jadavji T, et al. The use of intravenous gammaglobulin in the treatment of typical hemolytic uremic syndrome. Pediatr Nephrol. 1991;5:289–292
  107. Sheth KJ, Gill JC, Leichter HE. High-dose intravenous gamma globulin infusions in hemolytic-uremic syndrome: A preliminary report. Am J Dis Child. 1990;144:268–270
  108. Dervenoulas J, Tsirigotis P, Bollas G, et al. Efficacy of intravenous immunoglobulin in the treatment of thrombotic thrombocytopaenic purpura. A study of 44 cases. Acta Haematol. 2001;105:204–208
  109. Centurioni R, Bobbio-Pallavicini E, Porta C, et al. Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Italian Cooperative Group for TTP. Haematologica. 1995;80:325–331
  110. Finazzi G, Bellavita P, Falanga A, et al. Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Am J Hematol. 1992;41:165–169
  111. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:311S–337S(3 Suppl) (Erratum in: Chest 127:416, 2005]
  112. Winder A, Shoenfeld Y, Hochman R, et al. High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: A prompt response. J Clin Immunol. 1998;18:330–334
  113. Grau E, Linares M, Olaso MA, et al. Heparin-induced thrombocytopenia—response to intravenous immunoglobulin in vivo and in vitro. Am J Hematol. 1992;39:312–313
  114. Perrella O. Idiopathic thrombocytopenic purpura in HIV infection: therapeutic possibilities of intravenous immunoglobulins. J Chemother. 1990;2:390–393
  115. Jahnke L, Applebaum S, Sherman LA, et al. An evaluation of intravenous immunoglobulin in the treatment of human immunodeficiency virus-associated thrombocytopenia. Transfusion. 1994;34:759–764
  116. Schrappe-Bacher M, Rasokat H, Bauer P, et al. High-dose intravenous immunoglobulins in HIV-1–infected adults with AIDS-related complex and Walter-Reed 5. Vox Sang. 1990;59:3–14(Suppl 1)
  117. De Simone C, Tzantzoglou S, Santini G, et al. Clinical and immunologic effects of combination therapy with intravenous immunoglobulins and AZT in HIV-infected patients. Immunopharmacol Immunotoxicol. 1991;13:447–458
  118. Majluf-Cruz A, Luna-Castanos G, Huitron S, et al. Usefulness of a low-dose intravenous immunoglobulin regimen for the treatment of thrombocytopenia associated with AIDS. Am J Hematol. 1998;59:127–132
  119. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993;123:989–995
  120. Blanchette V. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344:703–707
  121. Duru F, Fisgin T, Yarali N, et al. Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy. Pediatr Hematol Oncol. 2002;19:219–225
  122. Fujisawa K, Iyori H, Ohkawa H, et al. A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura. Int J Hematol. 2000;72:376–383
  123. Imbach P, Wagner HP, Berchtold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet. 1985;2:464–468
  124. Khalifa AS, Tolba KA, el Alfy MS, et al. Idiopathic thrombocytopenic purpura in Egyptian children. Acta Haematol. 1993;90:125–129
  125. Mori PG, Lanza T, Mancuso G, et al. Treatment of acute idiopathic thrombocytopenic purpura (AITP): Cooperative Italian study group results. Pediatric. 1988;5:169–178
  126. Ozsoylu S, Sayli TR, Ozturk G. Oral megadose methylprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatric. 1993;10:317–321
  127. Rosthoj S, Nielsen S, Pedersen FK. Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura. Danish I.T.P. Study Group. Acta Paediatr. 1996;85:910–915
  128. Warrier I, Bussel JB, Valdez L, et al. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group. J Pediatr Hematol Oncol. 1997;19:197–201
  129. Tovo PA, Miniero R, Fiandino G, et al. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J Pediatr. 1984;105:676–677
  130. British Committee for Standards in Haematology General Haematology Task Force . Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574–596
  131. Beck CE, Nathan PC, Parkin PC, et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: A systematic review and meta-analysis of randomized controlled trials. J Pediatr. 2005;147:521–527
  132. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Review. Blood. 1996;88:3–40
  133. Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomised, multicentre trial. Lancet. 2002;359:23–29
  134. von dem Borne AE, Vos JJ, Pegels JG, et al. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J (Clin Res Ed). 1988;296:249–250
  135. Colovic M, Dimitrijevic M, Sonnenburg C, et al. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J. 2003;4:358–362
  136. Godeau B, Lesage S, Divine M, et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood. 1993;82:1415–1421
  137. Godeau B, Caulier MT, Decuypere L, et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: Results of a randomized trial comparing 0.5 and 1 g/kg B.W.. Br J Haematol. 1999;107:716–719
  138. Wehmeier A. Tolerability and efficacy of 5% versus 10% intravenous immunoglobulin preparation in adult patients with immune thrombocytopenia—a pilot study. Infusionsther Transfusionsmed. 1996;23:104–108(Suppl 4)
  139. Jacobs P, Wood L. The comparison of gammaglobulin to steroids in treating adult immune thrombocytopenia. An interim analysis. Blut. 1989;59:92–95
  140. Mueller-Eckhardt C, Kiefel V. High-dose IgG for post-transfusion purpura—revisited. Blut. 1988;57:163–167
  141. Ningsanond V. Infection associated hemophagocytic syndrome: A report of 50 children. J Med Assoc Thai. 2000;83:1141–1149
  142. Chen JS, Chang KC, Cheng CN, et al. Childhood hemophagocytic syndrome associated with Kikuchi's disease. Haematologica. 2000;85:998–1000
  143. Fort DW, Buchanan GR. Treatment of infection-associated hemophagocytic syndrome with immune globulin. J Pediatr. 1994;124:332
  144. Freeman B, Rathore MH, Salman E, et al. Intravenously administered immune globulin for the treatment of infection-associated hemophagocytic syndrome. J Pediatr. 1993;123:479–481
  145. Goulder P, Seward D, Hatton C. Intravenous immunoglobulin in virus associated haemophagocytic syndrome. Arch Dis Child. 1990;65:1275–1277
  146. Chen TL, Wong WW, Chiou TJ. Hemophagocytic syndrome: An unusual manifestation of acute human immunodeficiency virus infection. Int J Hematol. 2003;78:450–452
  147. Gill DS, Spencer A, Cobcroft RG. High-dose gamma-globulin therapy in the reactive haemophagocytic syndrome. Br J Haematol. 1994;88:204–206
  148. Kaneko M, Kuwabara S, Hatakeyama A, et al. Guillain-Barre and virus-associated hemophagocytic syndromes contracted simultaneously following Epstein-Barr viral infection. Neurology. 1997;49:870–871

PII: S0887-7963(07)00002-8

doi: 10.1016/j.tmrv.2007.01.001

Transfusion Medicine Reviews
Volume 21 , Pages S9-S56 , April 2007

Article Tools